Adia Med, Inc.
No SEC Form 4 filings for $ADIA in the last 30 days.
See all $ADIA insider activity →Adia Med, Inc. (OTCQB: ADIA) has fully repaid a $935K unsecured revolving credit facility to its CEO, Larry Powalisz. The repayment, completed in two installments, eliminates the company's debt and simplifies its remaining obligations to operating leases for its clinic and equipment. According to the company, this strengthens its financial position and balance sheet.
Adia Med, Inc. (ADIA) filed an SEC Form 8-K — Termination of a Material Definitive Agreement. Item 1.02. Termination of a Material Definitive Agreement On October 9, 2026, Adia Med, Inc. (the “Company”) fully repaid and discharged its unsecured revolving line of credit facility originally entered into on June 30, 2024, between Larry Powalisz, Chief Executive Officer of th
Adia Med (ADIA) sold 30% of Adia Labs to QCM Biologics for $1.5M, including $1M cash and a $500K note. The deal closed on 9/30/2026, with an option for QCM to buy more units by 9/30/2028. Despite retaining 70% economic ownership, voting power is split 50/50. According to the company, the sale monetizes a minority stake and adds a strategic partner.
Over the past 7 days, AlphAI's AI scored 3 news stories mentioning ADIA (Adia Med, Inc.). Coverage has been balanced: 0 bullish, 3 neutral, and 0 bearish.
Recent ADIA coverage spans corporate actions, mergers & acquisitions and financial news.
Balance sheet improvement removes debt and may modestly support the stock.
The repayment eliminates debt and interest expense, potentially improving balance‑sheet strength but unlikely to move the stock materially.
The stake sale reduces Adia Med's ownership to 70% but retains equal voting control, potentially affecting future valuation and liquidity.
Small cash inflow and change in ownership structure; limited effect on share price.
Potential dilution or ownership uncertainty could pressure the stock.
AlphAI scores every news story that mentions ADIA with an AI model for sentiment and relevance, and aggregates insider trades from Adia Med, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Adia Med, Inc. (OTCQB: ADIA) has fully repaid a $935K unsecured revolving credit facility to its CEO, Larry Powalisz. The repayment, completed in two installments, eliminates the company's debt and simplifies its remaining obligations to operating leases for its clinic and equipment. According to the company, this strengthens its financial position and balance sheet.
1 min readAdia Med, Inc. (ADIA) filed an SEC Form 8-K — Termination of a Material Definitive Agreement. Item 1.02. Termination of a Material Definitive Agreement On October 9, 2026, Adia Med, Inc. (the “Company”) fully repaid and discharged its unsecured revolving line of credit facility originally entered into on June 30, 2024, between Larry Powalisz, Chief Executive Officer of th
1 min readAdia Med (ADIA) sold 30% of Adia Labs to QCM Biologics for $1.5M, including $1M cash and a $500K note. The deal closed on 9/30/2026, with an option for QCM to buy more units by 9/30/2028. Despite retaining 70% economic ownership, voting power is split 50/50. According to the company, the sale monetizes a minority stake and adds a strategic partner.
1 min readAdia Med, Inc. (ADIA) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Item 1.01. Entry into a Material Definitive Agreement On September 30, 2026, Adia Med, Inc. (the “Company”), Adia Labs LLC, a Florida limited liability company and subsidiary of the Company (the “Labs Company”), and Live Oak Health LLC, a Florida limited liability company doing b
1 min readAdia Med, Inc. (ADIA) filed an SEC Form 8-K — Other Events. Exhibit 99.1 FORM 1.997. CIVIL COVER SHEET The civil cover sheet and the information contained in it neither replace nor supplement the filing and service of pleadings or other documents as required by law. This form must be filed by the plaintiff or petitioner with the Clerk of
1 min readAdia Nutrition (ADIA) has agreed to pay Lucosky Brookman LLP $150,000 for legal services related to its planned uplisting from the OTC Markets to the NASDAQ Capital Market and a bridge financing transaction. The fee structure includes payments upon closing of the bridge financing, filing of the registration statement, and completion of the uplisting.
2 min readAdia Nutrition, Inc. (ADIA) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement On August 19, 2026, Adia Nutrition, Inc. (the “Company”) entered into an engagement letter (the “Engagement Letter”) dated August 14, 2026 with Lucosky Brookman LLP (the “Firm”) pursuant to which the Firm will act as counsel t
1 min readAdia Med (OTCQB: ADIA) hired Lucosky Brookman LLP to assist with its planned uplisting from the OTC Markets to the NASDAQ Capital Market. The law firm will handle SEC filings, due diligence, and compliance services. Adia Med is a regenerative medicine company focused on stem cell therapies and related products.
1 min read
